Product Description
Mechanisms of Action: Protease Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | India | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Injuries/wounds Unspecified|Pancreatitis|Shock, Septic|Coronary Artery Disease|Other|Reperfusion Injury|Congenital Heart Defects|Inflammation
Phase 3: Nasopharyngeal Cancer|Mucositis|Oral Ulcer|Sepsis|Stomatitis
Phase 2: Lung Injury|COVID-19|Respiratory Aspiration|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome|Acute Lung Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2300074837 | N/A |
Recruiting |
Acute Kidney Injury|Coronary Disease|Kidney Diseases |
2033-08-31 |
|
ChiCTR2300072139 | N/A |
Recruiting |
Pancreatitis, Acute |
2026-06-30 |
|
ChiCTR2400080349 | N/A |
Not yet recruiting |
Sepsis |
2025-12-31 |
|
ChiCTR2400091262 | N/A |
Not yet recruiting |
Pancreatitis, Acute |
2025-07-01 |